FAS and metabolic dysfunction-associated steatotic liver disease: To further evaluate the underlying molecular mechanism in place, we performed in vitro assay tests, where we found that consistent with the phenotype, the lipogenic genes’ expression, including SREBP-1c and Fas, was dramatically suppressed by the knockdown of PLZF in the liver tissues obtained from db/db and DIO mice (Figure 2H and Supplementary Figure S2H), which contributed to the attenuation of NAFLD phenotype.